A Randomized, Double-blind, 2-period Parallel-arm Study to Assess the Immunogenicity of 2 Subcutaneous Doses of QL0605 (6 mg) Compared to 2 Subcutaneous Doses of US Neulasta PP (6 mg) in Healthy Male and Female Subjects
Latest Information Update: 05 Dec 2022
At a glance
- Drugs Pegfilgrastim (Primary)
- Indications Neutropenia
- Focus Pharmacodynamics
- Sponsors Qilu Pharmaceutical
- 09 Dec 2020 New trial record